Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case report

Typical CT findings of COVID-19 pneumonia in patients presenting with repetitive negative RT-PCR

B. Brogna a,*,1, E. Bignardi b,1, C. Brogna c, M. Alberigo a, M. Grappone d, A. Megliola a, P. Salvatore a, G. Fontanella e, E.M. Mazza a, L. Musto a, f

a Radiology Unit, “Frangipane” Hospital, ASL Avellino, Via V. Emanuele, Ariano irpino, 83031 Avellino, Italy
b Radiology Unit, “Cotugno Hospital, Naples, Via Quagliariello 54, Naples, 80131, Italy
c Neuropsychiatric Unit ASL Avellino, Via Degli Imbimbo 10/12, 83100 Avellino, Italy
d Laboratory Department “Frangipane” Hospital, ASL Avellino, Via V. Emanuele, Ariano irpino, 83031, Italy
e Department of Radiology, Sacred Hear of Jesus Hospital- Fatebenefratelli, 83100, Benevento, Italy
f Radiology Unit, “Crisculi” Hospital, ASL Avellino, Via Quadrivio, Sant’Angelo Dei Lombardi, 83054 Avellino, Italy

Keywords:
COVID-19
SARS-CoV-2
Repeated negative RT-PCR
Chest CT
Serological platforms

A R T I C L E  I N F O
Article history:
Received 1 June 2020
Received in revised form 10 September 2020
Accepted 14 September 2020
Available online 19 September 2020

A B S T R A C T
Multiple polymerase chain reaction (RT-PCR) is considered the gold standard diagnostic investigation for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

However, false negative multiple polymerase chain reaction (RT-PCR) results can be diagnostically challenging. We report three patients with history of fever and different clinical signs. During the height of the pandemic in Italy (March to May 2020), these patients underwent chest computed tomography (CT) scans that showed lung alterations typical of COVID-19 with multiple negative RT-PCR tests and positive serology for SARS-CoV-2. Two of the three patients showed residual pneumonia on CT after the onset of the first clinical signs. One patient presented with diarrhoea without respiratory symptoms. These cases suggest that in the COVID-19 pandemic period, to provide an earlier specific treatment in patients with positive serology, a chest CT scan can be useful in those presenting with a fever or a history of fever associated with persistent mild respiratory symptoms or with abdominal complaints despite repeated negative RT-PCR results.

© 2020 The College of Radiographers. Published by Elsevier Ltd. All rights reserved.

Introduction

Coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei Province, China. Despite travel restrictions, border controls, and quarantine measures adopted in many countries, the disease has rapidly spread around the world.

COVID-19 usually manifests with clinical symptoms related to pneumonia and, in fatal cases, with acute respiratory distress syndrome (ARDS). In some cases, asymptomatic and gastrointestinal or genitourinary complaints have been described as emerging presentations.1–4 To date, although multiple polymerase chain reaction (RT-PCR) is considered the gold standard diagnostic for SARS-CoV-2, there have been reports of low sensitivity ranging from 42% to 71%.5–8

False negative RT-PCR results are also a major concern for the clinical management of patients, especially for asymptomatic or mildly symptomatic individuals who continue to infect others while unaware of their increased transmission risk.3,6–9

In the presence of persistent clinical signs, additional diagnostic tools should therefore be considered.

We report three patients presenting with mild clinical signs and radiological findings typical of COVID-19 infection despite repeated negative RT-PCR results in the presence of positive serology.

Case presentations

The first case is a 60-year-old man who was referred to our emergency department due to mild dyspnoea. No history of
previous lung pneumonia was reported. Forty days before the onset of respiratory symptoms, he had a fever for seven days (39°C) after close contact with COVID-19 patients. Ten days after the first episode of fever, nasopharyngeal and oropharyngeal (NP/OP) swabs were performed by a family doctor who was negative for SARS-CoV-2. Ten days later, a second NP/OP swab was also negative; 20 days later, when the patient was admitted to our institution, further NP/OP swabs in the emergency room were also negative. He also presented with very mild lymphocytosis (3.27 × 10^3/μL) and a mildly elevated C-reactive protein (CRP) value (8 mg/dL); normal range values are 0–5 mg/dL. Arterial blood gas revealed an SpO2 of 94%. A rapid diagnostic test (RDT) was performed to detect the presence of SARS-CoV-2 IgG and negative IgM antibodies.

To determine an appropriate treatment and considering the positive epidemiological history (contact with COVID-19 patients), the previous presence of fever, persistent mild dyspnoea and the presence of SARS-CoV-2 IgG antibodies, a chest computed tomography (CT) scan was performed (Fig. 1). The CT scan showed the appearance of a typical COVID-19 radiological pattern according to international radiological guidelines, including ground glass opacities (GGOs) in both inferior lobes (Fig. 2) and the right middle lobe with posterior and subpleural distribution. Treatments with hydroxychloroquine sulfate and corticosteroid (methylprednisolone, 4 mg twice daily orally for 5 days) were administered with improvements in clinical conditions.

The second case is a 52-year-old woman who came to our emergency department due to persistent diarrhoea. Thirty days before the onset of the abdominal symptoms, she reported having had a fever for 14 days (38–40°C). On the tenth day of the fever, NP/OP swabs were negative for SARS-CoV-2 infection and was still negative 12 days later. Haematological evaluation on admission was normal, and the CRP value was in the normal range (2.9 mg/dL; normal range values are 1.5–3.0 mg/dL). Arterial blood gas revealed an SpO2 of 98%. Faecal specimens were negative for salmonella/ shigella/yersinia. On the basis of the previous persistent fever and diarrhoea, NP/OP swabs were performed in the hospital and were found to be negative for SARS-CoV-2. However, a rapid serological test confirmed the presence of SARS-CoV-2 IgM and IgG. A thoracic-abdominal CT scan showed residual pneumonia with some GGOs on both lungs; no abdominal alterations were seen on the abdominal CT scan (Fig. 3). Antiviral (lopinavir/ritonavir) treatment with antibiotic therapy was therefore started.

The third case is a 40-year-old woman who came to the emergency department having had a fever for seven days together with mild dyspnoea. NP/OP swabs were performed by the family doctor two days prior to admission were negative for SARS-CoV-2. Her laboratory values showed mild lymphopenia (1.3 × 10^3/μL; normal range values are 1.5–3.0 × 10^3/μL), and platelet counts were at the lower limit range (150,000/mm^3) (normal range values 150,000–400,000/mm^3). The CRP and D-dimer values were in the normal range. Arterial blood gas revealed an SpO2 of 90%. An RDT detected the presence of SARS-CoV-2 IgM. Therefore, a chest CT scan was performed, which showed bilateral and multifocal involvement of GGOs with predominance in the superior lobes and the middle lobe with peripheral and subpleural distribution suggesting probable COVID-19 infection (CLIA) detected the presence of SARS-CoV-2 IgG 15.72 (normal value 1) and negative IgM 0.9 (normal value 1).

**Discussion**

RT-PCR is usually used to confirm the microbiological diagnosis of SARS-CoV-2; however, its sensitivity depends on several factors, including the quality of the sampling, the sensitivity of the test kit, and the viral burden at the time of specimen collection. To date, several studies have reported a high sensitivity with CT scans, suggesting that they should be used in the diagnosis of COVID-19 together with RT-PCR. The reported sensitivities and specificities of CT scans for COVID-19 vary widely from “60%–98%” and “25%–63%”, respectively.

Current international radiological guidelines, including those from the Centers for Disease Control (CDC), the American College of Radiology (ACR) and the British Society of Thoracic Imaging (BSTI), do not recommend CT scans to diagnose COVID-19; instead, viral testing remains the only specific method of diagnosis. However, CT scans can be considered a diagnostic method when RT-PCR tests are not available, in the case of false-negative PCR assays and in areas with a high prevalence of COVID-19.

The CDC guidelines indicate that even if radiological findings are suggestive of COVID-19, the viral test is required; however, in all our cases, we performed a serological test together with a CT scan to determine specific treatments. As CT features tend to peak later (days 6–11) in the disease course, two of our patients presented after a long period of persistent clinical signs (all had fever), and a CT scan was performed later. In some cases, CT scans may highlight the first stage of COVID-19 before a positive RT-PCR test. Therefore, CT scans can be useful both in the early stage of COVID-19 and in symptomatic patients in the chronic phase, as they can reveal residual pneumonia.

The imaging features on chest CT usually vary depending on the time of scanning, disease stage during the follow-up, patient’s age, immunity status, underlying diseases, and drug interventions. Treatment with COVID-19 is currently based on anti-inflammatory and immunomodulatory drugs to reduce the immune response and antiviral drugs and to monitor coagulation function. Respiratory and circulation support are used for severe patients.

The use of a low-dose CT scan for the diagnosis of viral pneumonia enables patients with suspected SARS-CoV-2 infection to be quickly treated, thus optimizing patient management. The use of CT scans could also be very helpful in revealing complications of COVID-19, such as pneumomediastinum, pneumothorax, lung pulmonary embolism, and ARDS. Typical CT findings in individuals with COVID-19 have been reported to be GGOs, particularly on the peripheral and lower lobes, and bilateral multiple lobular and subsegmental areas of consolidation. Combinations of peripheral and central distribution have also been reported.

Non-typical CT findings have included pleural effusion, masses, cavitations and lymphadenopathies, which would therefore suggest alternative diagnoses.
Figure 2. Images a,b represent GGOs (black arrows) in a typical radiological pattern with peripheral and posterior distributions in the inferior lobes on the chest CT scan of the first patient.

Figure 3. Images a,b describe some GGOs (black arrows) with the typical peripheral distribution in the inferior lobes on the chest CT scan of the second patient.

Figure 4. Chest CT scan of the third patient describing GGOs with a peripheral distribution (black arrow) and also a peribronchovascular distribution (black dotted arrows) in the superior lobes (a); GGOs with a peripheral, posterior distribution and also a peribronchovascular distribution in the superior and inferior lobes (b); GGOs with a peripheral distribution in the right middle lobe (c); resolution at 20 days after therapy of the previous GGOs in the superior lobes.
Residual pneumonia with GGOs in two of our patients was visible more than 30 days after the onset of the initial symptoms; these patients had never been referred for previous pneumonia. Serological platforms are also useful to confirm SARS-CoV-2-specific antibody responses to reveal past infections, for rapid case identification, and in RT-PCR-negative patients, especially those who present later during the disease. The accuracy of serological tests is near 100% when samples are obtained 20 days after infection or first symptoms. Pooled specificities range from 96.6% to 99.7%. An RTD is typically a qualitative (positive or negative) lateral flow immunosassay with rapid time to results but with a low sensitivity of 66.0% (49.3%–79.3%), despite the high specificity (87–100%). Ong et al. showed that the sensitivity of RTD improved in patients with at least seven days of symptoms. Therefore, due to its high specificity, an RTD is considered a primary and rapid screening tool for COVID-19 and can accelerate decision making in the emergency room. CLIA is usually a quantitative, lab-based test with high sensitivity and specificity. The pooled sensitivity in measuring IgG or IgM using CLIA is 97.8% (46.2%–100%), and the specificity is approximately 98–100%.

In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 In two of our cases, clinicians used only rapid serological tests. In the third case, clinicians also used a quantitative test for the recent infection or past exposure.40 If a subject with a COVID-19 exposure history has positive IgM antibodies, this is indicative that the infection began more than 14 days previously and the immune system is actively producing an- tibodies. In these symptomatic cases, as in our second case, a positive RT-PCR result is not predictive of infection.34 The accuracy of rRT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. Eur open 2020;6(6). https://doi.org/10.1002/ep.200843. 200843:200843. 35 The accuracy of rRT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. Eur open 2020;6(6). https://doi.org/10.1002/ep.200843. 200843:200843. 35 The accuracy of rRT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. Eur open 2020;6(6). https://doi.org/10.1002/ep.200843. 200843:200843. 35 The accuracy of rRT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. Eur open 2020;6(6). https://doi.org/10.1002/ep.200843. 200843:200843. 35 The accuracy of rRT-PCR in SARS-CoV-2 disease: experience from an Italian COVID-19 unit. Eur open 2020;6(6). https://doi.org/10.1002/ep.200843. 200843:200843.
26. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. AJR Am J Roentgenol 2020;214(6):1280–6. https://doi.org/10.2214/AJR.20.22954.

27. Brogna B, Bignardi E, Salvatore P, Alberigo M, Brogna C, Musto L, et al. Unusual presentations of COVID-19 pneumonia on CT scans with spontaneous pneumomediastinum and loculated pneumothorax: a report of two cases and a review of the literature. Heart Lung 2020. https://doi.org/10.1016/j.hrtlng.2020.06.005.

28. Carotti M, Salaffi F, Sarzi-Puttini P, Agostini A, Borgheresi A, Giovagnoni A, et al. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. Radiol Med 2020;25(7):636–46. https://doi.org/10.1007/s11547-020-01237-4.

29. Hani C, Trieu NH, Saab I, Dangeard S, Bennani S, Revel MP, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 2020 May;101(5):263–8. https://doi.org/10.1016/j.diii.2020.03.014.

30. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Harris IM. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 2020 Jun 25;1(6):CD013652. https://doi.org/10.1002/14651858.

31. Bastos ML, Tavaziva C, Abidi SK, Campbell JR, Haraoui LP, Johnston, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 2020;370:m2516. https://doi.org/10.1136/bmj.m2516.

32. Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med 2020;12(546):eabc1931. https://doi.org/10.1126/scitransmed.abc1931. 2020.

33. Infantino M, Grossi V, Lari B, Bambi R, Perri A, Benucci M, et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol 2020. https://doi.org/10.1002/jmv.25932. 10.1002/jmv.25932.

34. Hoffman T, Nisien K, Krambrich J, Rosenberg B, Akaberi D, Å Lundkvist, et al. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol 2020;10(1):1754538. https://doi.org/10.1080/20008686.2020.1754538.

35. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Wang DQ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;1–4. https://doi.org/10.1038/s41591-020-0897.

36. Wu JL, Tseng WP, Lin CH, Lee TF, Chung MY, Chen SC, et al. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect 2020;81(3):435–42. https://doi.org/10.1080/20008686.2020.1754538.

37. Ong DS, Steijn J, Lindeboom FA, Koeleman JG. Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected COVID-19 presenting to the hospital. Clin Microbiol Infect 2020;26(8). https://doi.org/10.1016/j.cmi.2020.05.028. 1094.e7–1094.e10.

38. Imai K, Tabata S, Ikeda M, Noguchi S, Kitagawa Y, Maesaki S, et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. J Clin Virol 2020;128:104393. https://doi.org/10.1016/j.jcv.2020.104393.

39. Liu J, Liang S, Huabin W, Xiaoping X, Xiaodong L, Junqi W, et al. Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection. J Clin Lab Anal 2020:e23466. https://doi.org/10.1002/jcla.23466.

40. Jacofsky D, Jacofsky EM, Jacofsky M. Understanding antibody testing for covid-19. J Arthroplasty 2020;35(7S):574–81. https://doi.org/10.1016/j.arth.2020.04.055. 2020.